Proteomics International Laboratories Ltd. · ASX:PIQ
Proteomics International Laboratories — Shareholder Meeting (November 2020)
24 slides from Proteomics International Laboratories's shareholder meeting presentation, Nov 26, 2020
Slide 1: AGM Investor Presentation ASX Release
ASX Release 26 November2020 ASX code: PIQ AGM Investor Presentation Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) is pleased to release a copy of the AGM Investor Presentation to be provided by Dr Richard Lipscombe to shareholders at the Annual General Meeting to be
Slide 2: AGM Presentation: Building a Global Diagnostics Business
AGM Presentation 26th November 2020 BUILDING A GLOBAL ASX: PIQ DIAGNOSTICS BUSINESS
Slide 3: Disclaimer
Disclaimer ASX:PIQ This Presentation is provided by Proteomics International Laboratories Ltd (ASX: PIQ, Proteomics International, Proteomics, the Company). You should not rely upon anything in this presentation and/or any information obtained from the Company, its Directors or their associates in d
Slide 4: Corporate Overview
Corporate Overview ASX:PIQ Proteomics International Laboratories Ltd (ASX: PIQ) is a medical CORPORATE SNAPSHOT – 23/11/2020 technology company at the forefront of predictive diagnostics ASX code PIQ and bioanalytical services Share Price $0.53 DIAGNOSTICS Shares on issue (+ 5.6m options) 104.9m Pro
Slide 5: Board & Management
Terry Sweet FAICD, Chairman Board & Director of several listed companies over the past 30 years in both executive and non-executive capacities. Companies include XRFAfrica Scientific Ltd, where he was Management Managing Director for 4 years, Western Biotechnology Ltd, Heartlink Scientific Services
Slide 6: Promarker – Platform Technology
Promarker – Platform Technology ASX:PIQ PromarkerTM is a platform technology that can identify unique protein biomarkers ‘fingerprints’ The platform identifies and links the unique protein biomarkers to specific diseases, enabling Proteomics International to formulate commercial diagnostic tests 5
Slide 7: PromarkerD
PromarkerD ASX:PIQ PREDICTIVE TEST FOR DIABETIC KIDNEY DISEASE 6
Slide 8: Building a Global Diagnostics Business
Building a Global Diagnostics Business ASX:PIQ PromarkerD is revenue ready and Proteomics International is currently in discussions to bring the test to markets globally Enormous Market ✓ 463m adults have diabetes globally - 1 in 3 currently have DKD High Statistical Performance ✓ Peer reviewed publ
Slide 9: Market Size?
MARKET SIZE? 50% UNDIAGNOSED Nth America & Caribbean ASX:PIQ Europe ➢ Global IVD market worth South & Central America South-East Asia US$67 billion in 2019, Middle East & North Africa projected to reach $91 Western Pacific billion by 2027 Africa Sth/Ctrl America ➢ Proteomics market valued at US$24 b
Slide 10: PromarkerD - a Major Opportunity
PromarkerD - a Major Opportunity ASX:PIQ THE PROBLEM 463 million people have diabetes 1 in 3 diabetic adults currently have chronic kidney disease (CKD) There are no early symptoms of diabetic kidney disease - Kidney function can fall below 15-20% with no symptoms The current standard-of-care tests
Slide 11: PromarkerD Platforms
PromarkerD Platforms ASX:PIQ PREDICTIVE TEST for DIABETIC KIDNEY DISEASE PromarkerD assay can be readily ported to different pathology lab platforms Immunoassay Kit Laboratory Developed Test - LDT Automated Immunoassay ▪ Cost-effective, easy-to-use technology platforms ▪ Regulatory approval – Europe
Slide 12: PromarkerD in the Clinic
PromarkerD in the Clinic ASX:PIQ PREDICTIVE TEST for DIABETIC KIDNEY DISEASE PromarkerD patient reports use a traffic light scoring system for optimal performance A simple blood test that measures three plasma proteins combined with three clinical factors (age, cholesterol, eGFR) In published clinic
Slide 13: PromarkerD - Janssen Collaboration
PromarkerD - Janssen Collaboration ASX:PIQ Proteomics International and Janssen are studying the performance of PromarkerD in predicting decline in kidney function and treatment response in patients from a Janssen completed clinical trial STAGE 1 STUDY STAGE 2 STUDY ➢ Global multi-centre study of ov
Slide 14: PromarkerD - Route To Market
PromarkerD - Route To Market ASX:PIQ LABORATORY DEVELOPED TEST (LDT) IN VITRO DIAGNOSTIC TEST (IVD) ▪ Immunoassay or Mass spectrometry ▪ Immunoassay kit or automated machine platform ▪ Tests run via certified laboratories - both platforms standard to pathology laboratories ▪ The LDT permits fast ▪ A
Slide 15: PromarkerD - Market Opportunity
PromarkerD - Market Opportunity ASX:PIQ Market assumptions: Proteomics International patent portfolio and Market size ➢ Test is performed once per year per patient on average [Standard of care: High- risk patients are tested every 3-6 months; Low-risk every 2 years]. ➢ Test price of US$55-$150 [$55
Slide 16: PromarkerD - Recent Licence Agreements
PromarkerD - Recent Licence Agreements ASX:PIQ ITALY ISRAEL ➢ First licence agreement for high throughput ➢ First licence agreement for high throughput immunoassay – October 2020 immunoassay in the Middle East – November 2020 ▪ 3.7m people in Italy have type 2 diabetes (1 in 12) ▪ 1.1m people in Isr
Slide 17: Diagnostics Pipeline: Further Global Potential in New Markets
Further Global Potential in New Markets Proteomics endeavours to leverage its PromarkerTM Platform to develop and commercialise a suite of diagnostic tests Diagnostics Potential for faster market adoption for a new diagnostic test, Pipeline post a successful PromarkerD commercialisation Enormous mar
Slide 18: Diagnostics in Development: Endometriosis
Diagnostics in Development: Endometriosis ASX:PIQ What Is Endometriosis? A debilitating condition in which tissue that normally lines the uterus grows outside the uterus (on the ovaries, fallopian tubes or the intestines) The most common symptoms are chronic pain and menstrual irregularities Diagnos
Slide 19: Analytical Services
Analytical Services Proteomics International state-of-the-art biomarker analysis facilities ▪ World leading facility in Western Australia – Public Private Partnership co-invested >$4m including from Federal and State Government agencies ▪ Best in class Quality Control testing ▪ Biosimilars & biologi
Slide 20: Promarker Timeline & Upcoming Milestones
Promarker™ Timeline & Upcoming Milestones Two year targets and achievements Future targets November 2018 June 2020 Additional Proteomics enters Licensing deals Big pharma PromarkerD November 2019 for PromarkerD (Janssen) clinical collaboration with US with diagnostic/ CE Mark for study validates big
Slide 21: PIQ: Value Inflection Points 2021
PIQ: Value Inflection Points 2021 EXCEPTIONAL GLOBAL OPPORTUNITY ✓ Cutting-edge technology & proven in-house diagnostics platform ✓ PromarkerD test de-risked, patented and rolling-out in easy-to-use, low cost format ✓ Scalable licensing model with high margins and accessible to diverse range of diag
Slide 22: Contact
Contact ASX:PIQ Richard Lipscombe Dirk van Dissel Managing Director Corporate Advisor & Investor Relations T: +61 8 9389 1992 Candour Advisory E: enquiries@proteomicsinternational.com T: +61 408 326 367 www.proteomicsinternational.com E: dirk@candouradvisory.com.au Kyle Moss Corporate Advisor Euroz
Slide 23: Appendices: Peer Comparison
Appendices: Peer Comparison Addressable Market Share FY20 FY20 Net Stock Code Company Focus Market(s) Capitalisation Price Revenue Profit/Loss US$Bn DKD test based on AI and a combination of predictive blood-based biomarkers, £327m + For FY19 RENX.LSE 455p & genetic factors and electronic health US$
Slide 24: Treatments for DKD - SGLT2 Inhibitors
Appendices: Treatments for DKD - SGLT2 Inhibitors ASX:PIQ The Gliflozins Commercial Upside ▪ SGLT2 inhibitors, known as Gliflozins, treat diabetes ▪ PromarkerD could become a prognostic test for big by helping the kidneys to lower blood glucose levels pharma companies that are: ▪ Empagliflozin (Lill
Proteomics International Laboratories — Shareholder Meeting (November 2020) on 6ix